Table 2.

Changes in clinical data before and after administration of a SGLT-2 inhibitor.

Case	SGLT-2 inhibitor	Duration of SGLT-2inhibitor administration (months)	Data acquisition timing	Weight (kg)	HR (min−1)	SO2 (%)	Mean BP (mmHg)	HbA1C (%)	Ht (%)	Platelet (×109/L)	Albumin (g/dL)	Total bilirubin (mg/dL)	AST (IU/dL)	γGTP (IU/dL)	Na (mmol/L)	Creatinine (mg/dL)	eGFR (mL/min/1.73m2)	BNP (pg/mL)
1	Dapagliflozin 5 mg	3	Before	55	85	83	86	5.6	43	0.93	3.3	4.6	50	155	140	1.02	64	193
			After	53	87	91	87	—	44	0.78	3.1	3.9	45	139	141	1.28	50	277
2	Empagliflozin 10 mg	20	Before	80	114	91	93	7.3	52	3.15	2.9	1.5	26	32	138	1.21	56	231
			After	85	83	92	90	7.7	56	3.30	3.4	0.5	48	51	139	1.12	60	7
3	Dapagliflozin 5 mg	12	Before	116	91	85	86	6.5	41	1.57	2.8	1.0	41	78	140	0.84	72	52
			After	106	83	89	85	6.3	53	1.18	3.8	2.7	45	138	140	0.97	140	57
4	Dapagliflozin 5 mg	2	Before	34	92	81	93	3.2	35	2.35	1.8	0.1	16	17	137	0.60	113	43
			After	33	94	79	94	—	32	2.97	2.0	0.1	17	17	132	0.74	137	38
5	Dapagliflozin 5 mg	14	Before	69	103	88	84	7.8	60	1.64	2.9	1.7	55	108	125	1.52	72	101
			After	66	75	92	81	6.6	62	1.57	4.4	2.6	39	62	141	1.07	125	12
P value				0.345	0.224	0.138	0.224	—	0.224	0.892	0.079	0.715	0.892	0.224	0.465	0.685	0.500	0.345

P value < 0.05 means statistical significance when clinical data were compared before and after administration of a sodium glucose cotransporter-2 inhibitor using the Wilcoxon signed rank test. AST: aspartate aminotransferase; BNP: brain natriuretic peptide; BP: blood pressure; γGTP: gamma-glutamyl transpeptidase; HbA1C: haemoglobin A1C; HR: heart rate; Ht: haematocrit; eGFR: estimated glomerular filtration ratio; SGLT-2 inhibitor: sodium glucose cotransporter-2 inhibitor; SO₂: systemic oxygen saturation.